NanoString (NSTG) 10-Q7 Nov 222022 Q3 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 30, 2022	Nov. 01, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-35980
Entity Registrant Name	NANOSTRING TECHNOLOGIES, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-0094687
Entity Address, Address Line One	530 Fairview Avenue North
Entity Address, City or Town	Seattle
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98109
City Area Code	206
Local Phone Number	378-6266
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	NSTG
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		46,646,806
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001401708
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 117,069	$ 107,068
Short-term investments	113,384	241,821
Accounts receivable, net	27,273	40,130
Inventory, net	45,761	31,486
Prepaid expenses and other	15,221	7,115
Total current assets	318,708	427,620
Property and equipment, net	40,374	27,043
Operating lease right-of-use assets	18,586	19,226
Other assets	5,932	5,592
Total assets	383,600	479,481
Current liabilities:
Accounts payable	16,829	14,283
Accrued liabilities	4,898	6,765
Accrued compensation and other employee benefits	14,733	17,466
Customer deposits	1,071	1,278
Deferred revenue, current portion	8,026	7,474
Operating lease liabilities, current portion	5,382	4,889
Total current liabilities	50,939	52,155
Deferred revenue, net of current portion	3,757	3,527
Long-term debt, net	226,250	225,144
Operating lease liabilities, net of current portion	19,726	21,693
Total liabilities	300,672	302,519
Commitment and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 15,000 shares authorized; none issued	0	0
Common stock, $0.0001 par value, 150,000 shares authorized; 46,635 and 45,729 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	5	5
Additional paid-in capital	849,406	827,028
Accumulated other comprehensive loss	(1,301)	(318)
Accumulated deficit	(765,182)	(649,753)
Total stockholders’ equity	82,928	176,962
Total liabilities and stockholders’ equity	$ 383,600	$ 479,481

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	46,635,000	45,729,000
Common stock, shares outstanding (in shares)	46,635,000	45,729,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Revenue	$ 29,541	$ 37,150	$ 92,840	$ 102,630
Costs and expenses:
Cost of product revenue	13,723	17,154	44,353	48,258
Research and development	16,992	19,117	51,755	51,342
Selling, general and administrative	33,767	30,253	106,234	83,907
Total costs and expenses	64,482	66,524	202,342	183,507
Loss from operations	(34,941)	(29,374)	(109,502)	(80,877)
Other income (expense):
Interest income	774	153	1,331	502
Interest expense	(1,887)	(1,876)	(5,650)	(5,614)
Other income (expense), net	(579)	(223)	(1,286)	79
Total other expense, net	(1,692)	(1,946)	(5,605)	(5,033)
Net loss before provision for income tax	(36,633)	(31,320)	(115,107)	(85,910)
Provision for income tax	(57)	59	(322)	(83)
Net loss	$ (36,690)	$ (31,261)	$ (115,429)	$ (85,993)
Net loss per share - basic (in dollars per share)	$ (0.79)	$ (0.69)	$ (2.49)	$ (1.90)
Net loss per share - diluted (in dollars per share)	$ (0.79)	$ (0.69)	$ (2.49)	$ (1.90)
Weighted average shares used in computing basic net loss per share (in shares)	46,529	45,558	46,320	45,170
Weighted average shares used in computing diluted net loss per share (in shares)	46,529	45,558	46,320	45,170
Total product and service revenue
Revenue:
Revenue	$ 29,466	$ 36,924	$ 92,305	$ 101,950
Product
Revenue:
Revenue	24,605	32,523	78,561	90,028
Costs and expenses:
Cost of product revenue	10,159	13,286	33,592	37,090
Service revenue
Revenue:
Revenue	4,861	4,401	13,744	11,922
Costs and expenses:
Cost of product revenue	3,564	3,868	10,761	11,168
Collaboration revenue
Revenue:
Revenue	$ 75	$ 226	$ 535	$ 680

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (36,690)	$ (31,261)	$ (115,429)	$ (85,993)
Change in unrealized gain (loss) on available-for-sale debt securities	149	38	(983)	(107)
Comprehensive loss	$ (36,541)	$ (31,223)	$ (116,412)	$ (86,100)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Deficit Statement - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	[1]	Common Stock	Additional Paid-in Capital	Additional Paid-in Capital Cumulative Effect, Period of Adoption, Adjustment	[1]	Other Comprehensive Loss	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment	[1]
Balance at beginning (in shares) at Dec. 31, 2020				44,441
Balance at beginning at Dec. 31, 2020	$ 306,948	$ (51,012)		$ 4	$ 848,891	$ (58,543)		$ 83	$ (542,030)	$ 7,531
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued for stock options and restricted stock units (in shares)				726
Common stock issued for stock options and restricted stock units	2,250			$ 1	2,249
Common stock issued for employee stock purchase plan (in shares)				38
Common stock issued for employee stock purchase plan	1,192				1,192
Tax withholdings related to net share settlements of restricted stock units	(2,585)				(2,585)
Stock-based compensation	7,385				7,385
Net loss	(27,712)								(27,712)
Other comprehensive loss	(74)							(74)
Balance at end (in shares) at Mar. 31, 2021				45,205
Balance at end at Mar. 31, 2021	236,392			$ 5	798,589			9	(562,211)
Balance at beginning (in shares) at Dec. 31, 2020				44,441
Balance at beginning at Dec. 31, 2020	306,948	$ (51,012)		$ 4	848,891	$ (58,543)		83	(542,030)	$ 7,531
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(85,993)
Balance at end (in shares) at Sep. 30, 2021				45,639
Balance at end at Sep. 30, 2021	199,119			$ 5	819,630			(24)	(620,492)
Balance at beginning (in shares) at Mar. 31, 2021				45,205
Balance at beginning at Mar. 31, 2021	236,392			$ 5	798,589			9	(562,211)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued for stock options and restricted stock units (in shares)				297
Common stock issued for stock options and restricted stock units	2,255				2,255
Stock-based compensation	8,171				8,171
Net loss	(27,020)								(27,020)
Other comprehensive loss	(71)							(71)
Balance at end (in shares) at Jun. 30, 2021				45,502
Balance at end at Jun. 30, 2021	219,727			$ 5	809,015			(62)	(589,231)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued for stock options and restricted stock units (in shares)				111
Common stock issued for stock options and restricted stock units	1,043				1,043
Common stock issued for employee stock purchase plan (in shares)				26
Common stock issued for employee stock purchase plan	1,236				1,236
Stock-based compensation	8,336				8,336
Net loss	(31,261)								(31,261)
Other comprehensive loss	38							38
Balance at end (in shares) at Sep. 30, 2021				45,639
Balance at end at Sep. 30, 2021	199,119			$ 5	819,630			(24)	(620,492)
Balance at beginning (in shares) at Dec. 31, 2021				45,729
Balance at beginning at Dec. 31, 2021	176,962			$ 5	827,028			(318)	(649,753)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued for stock options and restricted stock units (in shares)				624
Common stock issued for stock options and restricted stock units	1,035			$ 0	1,035
Common stock issued for employee stock purchase plan (in shares)				49
Common stock issued for employee stock purchase plan	1,502				1,502
Tax withholdings related to net share settlements of restricted stock units	(1,505)				(1,505)
Stock-based compensation	7,785				7,785
Net loss	(39,500)								(39,500)
Other comprehensive loss	(974)							(974)
Balance at end (in shares) at Mar. 31, 2022				46,402
Balance at end at Mar. 31, 2022	145,305			$ 5	835,845			(1,292)	(689,253)
Balance at beginning (in shares) at Dec. 31, 2021				45,729
Balance at beginning at Dec. 31, 2021	176,962			$ 5	827,028			(318)	(649,753)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(115,429)
Balance at end (in shares) at Sep. 30, 2022				46,635
Balance at end at Sep. 30, 2022	82,928			$ 5	849,406			(1,301)	(765,182)
Balance at beginning (in shares) at Mar. 31, 2022				46,402
Balance at beginning at Mar. 31, 2022	145,305			$ 5	835,845			(1,292)	(689,253)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued for stock options and restricted stock units (in shares)				76
Common stock issued for stock options and restricted stock units	264				264
Stock-based compensation	6,493				6,493
Net loss	(39,239)								(39,239)
Other comprehensive loss	(158)							(158)
Balance at end (in shares) at Jun. 30, 2022				46,478
Balance at end at Jun. 30, 2022	112,665			$ 5	842,602			(1,450)	(728,492)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued for stock options and restricted stock units (in shares)				56
Common stock issued for stock options and restricted stock units	117				117
Common stock issued for employee stock purchase plan (in shares)				101
Common stock issued for employee stock purchase plan	1,168				1,168
Stock-based compensation	5,519				5,519
Net loss	(36,690)								(36,690)
Other comprehensive loss	149							149
Balance at end (in shares) at Sep. 30, 2022				46,635
Balance at end at Sep. 30, 2022	$ 82,928			$ 5	$ 849,406			$ (1,301)	$ (765,182)

[1] (1) Effective January 1, 2021, the Company adopted Accounting Standard Update No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40). See Note 2. Basis of Presentation and Summary of Significant Accounting Policies and Note 9. Long-term Debt, Net for more information.

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities
Net loss	$ (115,429)	$ (85,993)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	19,644	23,689
Depreciation and amortization	5,151	4,347
Amortization of deferred financing costs	1,105	1,069
Amortization of premium (accretion of discount) on short-term investments, net	1,481	(2,436)
Non-cash operating lease cost	3,012	2,553
Allowance for inventory obsolescence and accounts receivable credit loss	2,318	2,258
Changes in operating assets and liabilities:
Accounts receivable	11,698	(4,739)
Inventory	(16,109)	(10,348)
Prepaid expenses and other assets	(8,057)	(8,265)
Accounts payable	2,793	6,975
Accrued liabilities	(3,016)	(1,161)
Accrued compensation and other employee benefits	(2,348)	958
Customer deposits	(207)	(304)
Deferred revenue and other liabilities	1,040	1,540
Operating lease liabilities	(3,601)	(3,173)
Net cash used in operating activities	(100,525)	(73,030)
Investing activities
Purchases of property and equipment	(11,497)	(4,704)
Purchase of internal-use software assets	(5,343)	(651)
Payments to Acquire Intangible Assets	(750)	0
Proceeds from sale of short-term investments	7,700	4,000
Proceeds from maturity of short-term investments	167,774	24,764
Purchases of short-term investments	(49,500)	(260,239)
Net cash provided by (used in) investing activities	108,384	(236,830)
Financing activities
Tax withholdings related to net share settlements of restricted stock units	(1,504)	(2,585)
Proceeds from issuance of common stock for employee stock purchase plan	2,669	2,427
Proceeds from exercise of stock options	1,417	5,547
Repayment of finance lease obligations	(257)	(170)
Net cash provided by financing activities	2,325	5,219
Effect of exchange rate changes on cash and cash equivalents	(183)	(40)
Net increase (decrease) in cash and cash equivalents	10,001	(304,681)
Cash and cash equivalents
Beginning of period	107,068	411,848
End of period	117,069	107,167
Supplemental disclosures
Operating lease right-of-use assets obtained in exchange for lease obligations	2,126	0
Finance lease right-of-use assets obtained in exchange for lease obligations	$ 0	$ 448

Description of Business

Description of Business	9 Months Ended
Description of Business	Sep. 30, 2022
Accounting Policies [Abstract]
Description of Business	Description of the BusinessNanoString Technologies, Inc. (the “Company”) was incorporated in the state of Delaware on June 20, 2003. The Company’s headquarters is located in Seattle, Washington. NanoString develops, manufactures and markets technologies that unlock scientifically valuable and clinically actionable information from minute amounts of biological material, primarily for life science researchers in the fields of genomics and proteomics. The Company’s mission is to provide a portfolio of solutions that allow our customers to map the universe of biology, enabling scientific exploration that may lead to new therapies that can improve the human condition. The Company’s proprietary chemistries enable the direct detection, identification, and quantification of individual target molecules in biological samples by attaching unique molecular reporters to each target molecule of interest. The Company currently markets and sells two platforms based on its proprietary technologies, its nCounter Analysis System, and its GeoMx Digital Spatial Profiler, or GeoMx DSP. The Company has one additional product platform under development, its CosMx Spatial Molecular Imager, or CosMx SMI, that is expected to become commercially available by the end of 2022. The Company’s platforms are comprised of instruments and related consumables and services. The Company is also developing the AtoMx Spatial Informatics Platform, or AtoMx SIP, a cloud-based informatics portal for use with GeoMx DSP and CosMx SMI that is expected to become commercially available by the end of 2022. The Company sells its platforms primarily to academic, government, biopharmaceutical, and clinical laboratory customers.

Concentration of Risks

Concentration of Risks	9 Months Ended
Concentration of Risks	Sep. 30, 2022
Risks and Uncertainties [Abstract]
Concentration of Risks	5. Concentration of Risks Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash and cash equivalents, short-term investments, and accounts receivable. Cash is invested in accordance with the Company’s investment policy, which includes guidelines intended to minimize and diversify credit risk. Most of the Company’s investments are not federally insured. The Company has credit risk related to the collectability of its accounts receivable. The Company performs initial and ongoing evaluations of its customers’ credit history or financial position and generally extends credit on account without collateral. Additionally, the Company evaluates collectability risk over the life of its receivables in order to establish an appropriate reserve for certain receivables that may become uncollectible in future periods. The Company has not experienced significant credit losses to date. During the three and nine months ended September 30, 2022 and 2021, the Company had no customers that individually represented more than 10% of total revenue. The Company had no customers that represented more than 10% of total accounts receivable as of September 30, 2022 or December 31, 2021. The Company is also subject to supply chain risks related to the outsourcing of the manufacturing and production of its instruments to sole suppliers. Although there are a limited number of manufacturers for instruments of this type, the Company believes that other suppliers could provide similar products on comparable terms. Similarly, the Company sources certain raw materials used in the manufacture of consumables from sole suppliers. The impact of the COVID-19 global pandemic has not had a significant impact on the Company’s ability to source raw materials or its instruments to date. However, a change in or loss of suppliers could cause a delay in manufacturing and a possible loss of sales, which would adversely affect operating results. Should COVID-19 (or a variant thereof) continue to impact the global economy at the same or heightened levels during future periods, or if certain geographies where the Company’s key suppliers or manufacturing facilities are located are more severely impacted than others, this could negatively impact the Company’s ability to manufacture new products, fulfill customer orders, and collect from customers, which could adversely affect future operating results.

Short-term Investments

Short-term Investments	9 Months Ended
Short-term Investments	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Short-term Investments	Short-term Investments Short-term investments consisted of available-for-sale and equity securities as follows (in thousands): Type of securities as of September 30, 2022 Amortized Gross Gross Fair value Corporate debt securities $ 80,363 $ — $ (841) $ 79,522 Government-related debt securities 31,039 — (423) 30,616 Asset-backed securities 3,283 — (37) 3,246 Total available-for-sale debt securities $ 114,685 $ — $ (1,301) $ 113,384 Type of securities as of December 31, 2021 Amortized Gross Gross Fair value Corporate debt securities $ 177,375 $ 3 $ (195) $ 177,183 Government-related debt securities 33,134 2 (97) 33,039 Asset-backed securities 31,631 — (32) 31,599 Total available-for-sale debt securities $ 242,140 $ 5 $ (324) $ 241,821 The fair values of available-for-sale debt securities by contractual maturity were as follows (in thousands): September 30, 2022 December 31, 2021 Maturing in one year or less $ 110,138 $ 174,534 Maturing in one to three years 3,246 67,287 Total available-for-sale debt securities $ 113,384 $ 241,821 The Company has both the intent and ability to sell its available-for-sale debt securities maturing greater than one year within 12 months from the balance sheet date and, accordingly, has classified these securities as current in the condensed consolidated balance sheets. The following table summarizes investments that have been in a continuous unrealized loss position as of September 30, 2022 (in thousands). Less than 12 months 12 months or greater Total Fair Value Gross unrealized losses Fair Value Gross unrealized losses Fair Value Gross unrealized losses Corporate debt securities $ 44,749 $ (521) $ 14,825 $ (320) $ 59,574 $ (841) Government-related debt securities 22,636 (391) 7,981 (32) 30,617 (423) Asset Backed Securities 3,246 (37) — — 3,246 (37) Total $ 70,631 $ (949) $ 22,806 $ (352) $ 93,437 $ (1,301) The Company invests in securities that are rated investment grade or better. The unrealized losses on available-for-sale debt securities as of September 30, 2022 were caused primarily by interest rate increases. The Company reviews the individual securities in its portfolio for impairment when events indicate the fair value of the investments may be below the carrying value. The Company reviews the individual securities in its portfolio for indications that unrealized losses are credit related and require an allowance to be recorded at the present value of the future expected cash flows. The Company determined unrealized losses were not for credit losses and therefore did not record an allowance related to its available-for-sale debt investments for the three and nine month periods ended September 30, 2022. The Company did not record any impairment charges related to its available-for-sale debt investments for the three and nine month periods ended September 30, 2022.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Litigation Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. 10x Genomics On May 6, 2021, 10x Genomics, Inc. and Prognosys Biosciences, Inc. (“Prognosys”) filed a complaint, on May 19, 2021, an amended complaint, and on May 4, 2022, a second amended complaint, against the Company in the U.S. District Court for the District of Delaware. The amended complaint alleges that certain of the Company’s products, services and components, including those sold by the Company for use in connection with its GeoMx DSP system (the “Identified GeoMx Products”), infringe seven patents owned by Prognosys: (a) U.S. Patent No. 10,472,669,“Spatially encoded biological assays,” (b) U.S. Patent No. 10,961,566,“Spatially encoded biological assays,” (c) U.S. Patent No. 10,983,113,“Spatially encoded biological assays,” (d) U.S. Patent No. 10,996,219,“Spatially encoded biological assays,” (e) U.S. Patent No. 11,001,878, “Spatially encoded biological assays,” (f) U.S. Patent No. 11,008,607, “Spatially encoded biological assays,” and (g) U.S. Patent No. 11,293,917, “Systems for analyzing target biological molecules via sample imaging and delivery of probes to substrate wells” (the “Asserted Prognosys Patents”). The amended complaint seeks, among other relief, injunctive relief and unspecified damages (including treble damages and attorneys’ fees) in relation to the Company’s making, using, selling, offering to sell, exporting and/or importing in the United States the Identified GeoMx Products, as well as the alleged infringement by others of the Asserted Prognosys Patents through their use of the Identified GeoMx Products. The Company has evaluated the plaintiffs’ claims and does not believe that its activities infringe any patent rights held by the plaintiffs. On November 17, 2021, the Court granted the Company’s motion to dismiss the plaintiffs’ claims of pre-suit indirect infringement and willful infringement with leave to amend the complaint. Discovery is in progress. A trial is scheduled for August 2023. The Company intends to vigorously defend itself in this ongoing litigation. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in this case. On February 28, 2022, 10x Genomics, Inc. and President and Fellows of Harvard College (“Harvard”) filed a complaint, and on May 12, 2022, an amended complaint, against the Company in the U.S. District Court for the District of Delaware. The complaint alleges that certain of the Company’s products, services and components, including those sold by the Company for use in connection with its CosMx SMI system (the “Identified CosMx Products”), infringe five patents owned by Harvard: (a) U.S. Patent No. 10,227,639, “Compositions and Methods for Analyte Detection,” (b) U.S. Patent No. 11,021,737, “Compositions and Methods for Analyte Detection,” (c) U.S. Patent No. 11,293,051, “Compositions and Methods for Analyte Detection”, (d) U.S. Patent No. 11,293,052, “Compositions and Methods for Analyte Detection,” and (e) U.S. Patent No. 11,293,054, “Compositions and Methods for Analyte Detection” (the “Asserted Harvard Patents”). The complaint seeks, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to the Company’s making, using, selling, offering to sell, exporting and/or importing in the United States the Identified CosMx Products. The Company has evaluated the plaintiffs’ claims and does not believe that its activities infringe any patent rights held by the plaintiffs. On August 16, 2022, the Company filed an amended answer to the complaint with counterclaims alleging that 10x Genomics’ Visium Spatial Gene Expression system and related products and services infringe the Company’s U.S. Patent No. 11,377,689, “Chemical Compositions and Uses Thereof.” The Company seeks, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to 10x Genomics’ making, using, selling, offering to sell, exporting and/or importing in the United States the Visium system and related products and services. A trial is scheduled for June 2024. The Company intends to vigorously defend itself in this ongoing litigation. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in this case. In May 2022, the Company was notified of a complaint, dated March 4, 2022, naming the Company and its wholly-owned subsidiary, NanoString Technologies Germany GmbH, which 10x Genomics, Inc. filed in the Munich Regional Court I in Germany, alleging that certain of the Company's products and services, including those for use in connection with the Company’s CosMx SMI system, infringe European Patent No. 2794928B1 (“EP 2794928B1”), which is owned by Harvard. The Company has evaluated the claims and does not believe that its activities infringe any patent rights held by the plaintiff. A hearing is scheduled for March 2023 in this proceeding. On July 29, 2022, the Company, through its German subsidiary, filed a nullity action with the German Federal Patent Court in Munich requesting a judgment that EP 2794928B1, as in effect for Germany, be declared invalid and be revoked in its entirety. The Company believes a preliminary opinion in the nullity proceeding will be issued prior to the March 2023 hearing in the infringement proceeding. The Company intends to vigorously defend itself in this litigation. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in this case. On October 20, 2022, the Company filed suit against 10x Genomics, Inc. in the U.S. District Court for the District of Delaware alleging that 10x Genomics’ Visium Spatial Gene Expression system and related products and services infringe the Company's U.S. Patent No. 11,473,142, “Chemical Compositions and Uses Thereof.” The Company seeks, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to 10x Genomics’ making, using, selling, offering to sell, exporting and/or importing in the United States the Visium system and related products and services. Contingencies Other than the pending litigations with 10x Genomics and its co-plaintiffs, the Company is not engaged in any material legal proceedings. The Company is involved in other legal proceedings from time to time arising in the normal course of business. Additionally, the Company operates in various states and local jurisdictions for which sales, occupation, or franchise taxes may be payable to certain taxing authorities. Management believes that the outcome of these proceedings and any amounts that may become payable to certain taxing authorities will not have a material impact on the Company’s financial condition, results of operations, or liquidity.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements reflect the accounts of the Company and its wholly-owned subsidiaries. The unaudited condensed consolidated balance sheet at December 31, 2021 has been derived from the audited consolidated financial statements at that date but does not include all information and disclosures required by generally accepted accounting principles in the United States of America (“U.S. GAAP”) for annual financial statements. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and U.S. GAAP for unaudited condensed consolidated financial information. Accordingly, they do not include all information and footnotes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and results of its operations as of and for the periods presented. Unless indicated otherwise, all amounts presented in financial tables are presented in thousands, except for per share and par value amounts. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Given the global economic climate and additional or unforeseen effects from the COVID-19 pandemic, certain estimates are becoming more challenging, and actual results could differ materially from those estimates. The results of the Company’s operations for the three and nine month periods ended September 30, 2022 are not necessarily indicative of the results to be expected for the full year or for any other period. Revenue Recognition The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration expected to be received in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has transferred control of a product or service to the customer, meaning the customer has the ability to use and obtain the benefit of the product or service. The Company recognizes revenue for satisfied performance obligations only when there are no uncertainties regarding payment terms or transfer of control. The Company generates the majority of its revenue from sales of its proprietary GeoMx DSP and nCounter Analysis systems, and related consumables. Services consist of instrument service contracts for maintenance, repair and other support related to customer owned instruments, and also certain service fees for assay processing and data analysis and reporting. Leases The Company determines if an arrangement is a lease at inception of a contract. The Company’s leasing portfolio is comprised of operating leases primarily for general office, manufacturing, and research and development purposes, and financing leases for equipment. Operating and financing lease liabilities and the corresponding right-of-use assets are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Operating lease right-of-use assets are reduced by lease incentives included in the agreement. As the existing leases do not contain an implicit interest rate, the Company estimates its incremental borrowing rate based on information available at commencement date in determining the present value of future payments. The Company includes options to extend the lease in the lease liability and right-of-use asset when it is reasonably certain that the option will be exercised. Operating lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Finance lease assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or, in the instance where title does not transfer at the end of the lease term, the lease term. The interest component of a finance lease is included in interest expense and recognized using the effective interest method over the lease term. For our short-term leases, we recognize lease payments as an expense on a straight-line basis over the lease term. Capitalized Internal Use Software Costs The Company capitalizes certain development costs incurred in connection with software development for internal use software platforms. Costs incurred in the preliminary stages of development are expensed as incurred. Once software has reached the development stage, internal and external costs, if direct, are capitalized until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized internal use software development costs are included in property and equipment and are amortized on a straight-line basis over the estimated useful life and are included in depreciation and amortization within operating expenses in our consolidated statements of operations. Capitalized internal use software development costs were $10.2 million and $4.0 million as of September 30, 2022 and December 31, 2021, respectively.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	9 Months Ended
Revenue from Contracts with Customers	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	Revenue from Contracts with Customers The Company operates as a single reportable segment. The Company has one sales force that sells the Company’s nCounter Analysis systems, its GeoMx DSP system, its CosMx SMI system, and the consumables and services related to these platforms. Disaggregated Revenues The following table of total revenue is based on the geographic location of end users or distributors who purchase products and services, and of our collaborators. For sales to distributors, their geographic location may be different from the geographic location of the ultimate end customer. For collaboration agreements, revenues are derived from partners located primarily in the United States. Americas consists of the United States, Canada, Mexico, and South America; and Asia Pacific includes Japan, China, South Korea, Singapore, Malaysia, India, and Australia. The following table provides information about disaggregated revenue by major product line and primary geographic market (in thousands): Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Americas Europe and Middle East Asia Pacific Total Americas Europe and Middle East Asia Pacific Total Product revenue: Instruments $ 4,835 $ 2,171 $ 1,017 $ 8,023 $ 16,343 $ 6,132 $ 4,189 $ 26,664 Consumables 12,044 3,687 851 16,582 37,017 11,778 3,102 51,897 Total product revenue 16,879 5,858 1,868 24,605 53,360 17,910 7,291 78,561 Service revenue 3,362 1,259 240 4,861 9,589 3,486 669 13,744 Total product and service revenue 20,241 7,117 2,108 29,466 62,949 21,396 7,960 92,305 Collaboration revenue 75 — — 75 535 — — 535 Total revenues $ 20,316 $ 7,117 $ 2,108 $ 29,541 $ 63,484 $ 21,396 $ 7,960 $ 92,840 Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 Americas Europe and Middle East Asia Pacific Total Americas Europe and Middle East Asia Pacific Total Product revenue: Instruments $ 8,514 $ 3,827 $ 2,154 $ 14,495 $ 21,650 $ 10,230 $ 6,176 $ 38,056 Consumables 13,120 3,682 1,226 18,028 36,928 11,538 3,506 51,972 Total product revenue 21,634 7,509 3,380 32,523 58,578 21,768 9,682 90,028 Service revenue 2,957 1,149 295 4,401 8,138 3,010 774 11,922 Total product and service revenue 24,591 8,658 3,675 36,924 66,716 24,778 10,456 101,950 Collaboration revenue 226 — — 226 680 — — 680 Total revenues $ 24,817 $ 8,658 $ 3,675 $ 37,150 $ 67,396 $ 24,778 $ 10,456 $ 102,630 Total revenue in the United States was $19.0 million, $23.9 million, $60.9 million and $65.0 million for the three and nine month periods ended September 30, 2022 and 2021, respectively. The Company’s assets are primarily located in the United States and therefore are not allocated to any specific geographic region. Contract balances and remaining performance obligations Contract liabilities are comprised of the current and long-term portions of deferred revenue of $11.4 million and $10.3 million as of September 30, 2022 and December 31, 2021, respectively, and customer deposits of $1.1 million and $1.3 million as of September 30, 2022 and December 31, 2021, respectively, included within the condensed consolidated balance sheets. Total contract liabilities increased by $0.8 million as of September 30, 2022 as a result of additional deferred revenue of $9.6 million associated primarily with new or extended service contracts partially offset by the recognition of previously deferred revenue and customer deposits of $8.8 million for the completion of certain performance obligations during the period. The Company recorded contract assets of $1.0 million and $0.7 million as of September 30, 2022 and December 31, 2021, related to revenues recognized, but not yet invoiced to customers. The Company’s contractual payment terms for its contracts with customers approximates 45 days on average. As of September 30, 2022, unsatisfied or partially unsatisfied performance obligations related to undelivered products and service contracts were $12.5 million and are expected to be completed over the term of the related contract or as products are delivered.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
Net Loss Per Share	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per ShareNet loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding. Convertible notes, outstanding options to purchase common stock, restricted stock units and common stock warrants have not been included in the calculation of diluted net loss per share because to do so would be anti-dilutive. Accordingly, the numerator and the denominator used in computing both basic and diluted net loss per share for each period are the same. The following shares were excluded from the computation of basic and diluted net loss per share for the periods presented (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Options to purchase common stock 1,788 2,138 1,866 2,349 Restricted stock units 2,218 1,318 1,777 1,356 Common stock warrants 471 471 471 471

Fair Value Measurements

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company establishes the fair value of its assets and liabilities using the price that would be received to sell an asset or paid to transfer a financial liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy is used to measure fair value. The three levels of the fair value hierarchy are as follows: • Level 1 — Quoted prices in active markets for identical assets and liabilities. • Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. • Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The recorded amounts of certain financial instruments, including cash, accounts receivable, prepaid expenses and other, accounts payable and accrued liabilities, approximate fair value due to their relatively short-term maturities. The recorded amount of the Company’s long-term debt can be determined based on the estimated or actual bid prices of the Convertible Senior Notes in an over-the-counter market, which are classified as a Level 2 financial instrument. The Company’s investments by level within the fair value hierarchy were as follows (in thousands): Fair value measurement using: Type of securities as of September 30, 2022 Level 1 Level 2 Level 3 Total Cash equivalents: Money market fund $ 109,209 $ — $ — $ 109,209 Short-term investments: Corporate debt securities — 79,522 — 79,522 Government-related debt securities — 30,616 — 30,616 Asset-backed securities — 3,246 — 3,246 Total $ 109,209 $ 113,384 $ — $ 222,593 Fair value measurement using: Type of securities as of December 31, 2021 Level 1 Level 2 Level 3 Total Cash equivalents: Money market fund $ 98,247 $ — $ — $ 98,247 Short-term investments: Corporate debt securities — 177,183 — 177,183 Government-related debt securities — 33,039 — 33,039 Asset-backed securities — 31,599 — 31,599 Total $ 98,247 $ 241,821 $ — $ 340,068 In March 2020, the Company issued $230.0 million of Convertible Notes as described in more detail in Note 9. Long-term Debt, Net. As of September 30, 2022, the fair value of the Convertible Notes was $194.9 million.

Inventory

Inventory	9 Months Ended
Inventory	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory, net of related allowances, consisted of the following as of the date indicated (in thousands): September 30, 2022 December 31, 2021 Raw materials $ 7,507 $ 5,135 Work in process 15,140 9,916 Finished goods 23,114 16,435 Total inventory, net $ 45,761 $ 31,486

Long-term Debt

Long-term Debt	9 Months Ended
Long-term Debt	Sep. 30, 2022
Debt Disclosure [Abstract]
Long-term Debt	Long-term Debt, Net In March 2020, the Company issued $230.0 million in aggregate principal amount of its Convertible Notes in a private offering. The Convertible Notes are governed by an indenture dated March 9, 2020 between the Company and U.S. Bank, National Association, as trustee. The Company received net proceeds from the offering of $222.6 million. The Convertible Notes bear interest at a rate of 2.625% per year, payable semi-annually in arrears on March 1st and September 1st. The Convertible Notes may bear additional interest under specified circumstances relating to the Company’s failure to comply with its reporting obligations under, or if the Convertible Notes are not freely tradeable as required by, the indenture governing the Convertible Notes. Upon conversion, the Convertible Notes will be convertible into cash, shares of common stock or a combination of cash and shares of common stock, at the Company’s election. The Convertible Notes are general unsecured senior obligations and will mature on March 1, 2025, unless earlier repurchased, redeemed or converted, subject to satisfaction of certain conditions and during the periods described below. The initial conversion rate for the Convertible Notes is 20.9161 shares of common stock, par value $0.0001 per share, per $1,000 principal amount of Convertible Notes (which is equivalent to an initial conversion price of approximately $47.81 per share). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that may occur prior to the maturity date or if the Company issues a notice of redemption, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such corporate event or in connection with such redemption, as the case may be, in certain circumstances. The Company incurred approximately $7.4 million of debt issuance costs, which primarily consisted of underwriting, legal and other professional fees directly associated with the issuance. The debt issuance costs are amortized to interest expense using the effective interest method over five years, the contractual term of the Convertible Notes, with an effective interest rate of 3.3%. The Company monitors the provision of the Convertible Notes that allow for certain conversion rights at each quarterly reporting date in order to determine whether the Convertible Notes are convertible or subject to an event triggering potential redemption during the prescribed measurement periods. As of the date of this report, none of the outstanding convertible notes had been redeemed by the Company. Based on the closing price of our common stock of $12.77 on the last trading day of the quarter, the if-converted values of the Convertible Notes did not exceed the remaining principal balance as of September 30, 2022. All future principal payments related to the Convertible Notes are due in March 2025. The outstanding balances of the Company’s Convertible Notes and previously outstanding term loan consisted of the following (in thousands): September 30, 2022 December 31, 2021 Outstanding principal of Convertible Note $ 230,000 $ 230,000 Less: unamortized issuance costs (3,750) (4,856) Long-term debt, net $ 226,250 $ 225,144 The following table sets forth total interest expense recognized related to the Convertible Notes (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Contractual interest expense $ 1,509 $ 1,509 $ 4,528 $ 4,528 Amortization of issuance costs 373 361 1,105 1,069 Total interest expense $ 1,882 $ 1,870 $ 5,633 $ 5,597

Subsequent Event (Notes)

Subsequent Event (Notes)	9 Months Ended
Subsequent Event (Notes)	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Event	Subsequent EventIn November 2022, we announced a reduction in force that is expected to result in the termination of approximately 10% of our global workforce and the Company currently estimates it will incur between approximately $3.0 million and $4.0 million of costs, consisting primarily of cash severance costs, which the Company expects to recognize in the fourth quarter of 2022. We expect to substantially complete the reduction in force by December 31, 2022.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	The accompanying unaudited condensed consolidated financial statements reflect the accounts of the Company and its wholly-owned subsidiaries. The unaudited condensed consolidated balance sheet at December 31, 2021 has been derived from the audited consolidated financial statements at that date but does not include all information and disclosures required by generally accepted accounting principles in the United States of America (“U.S. GAAP”) for annual financial statements. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and U.S. GAAP for unaudited condensed consolidated financial information. Accordingly, they do not include all information and footnotes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and results of its operations as of and for the periods presented. Unless indicated otherwise, all amounts presented in financial tables are presented in thousands, except for per share and par value amounts. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Given the global economic climate and additional or unforeseen effects from the COVID-19 pandemic, certain estimates are becoming more challenging, and actual results could differ materially from those estimates. The results of the Company’s operations for the three and nine month periods ended September 30, 2022 are not necessarily indicative of the results to be expected for the full year or for any other period.
Revenue Recognition	The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration expected to be received in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has transferred control of a product or service to the customer, meaning the customer has the ability to use and obtain the benefit of the product or service. The Company recognizes revenue for satisfied performance obligations only when there are no uncertainties regarding payment terms or transfer of control.The Company generates the majority of its revenue from sales of its proprietary GeoMx DSP and nCounter Analysis systems, and related consumables. Services consist of instrument service contracts for maintenance, repair and other support related to customer owned instruments, and also certain service fees for assay processing and data analysis and reporting.
Leases	The Company determines if an arrangement is a lease at inception of a contract. The Company’s leasing portfolio is comprised of operating leases primarily for general office, manufacturing, and research and development purposes, and financing leases for equipment. Operating and financing lease liabilities and the corresponding right-of-use assets are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Operating lease right-of-use assets are reduced by lease incentives included in the agreement. As the existing leases do not contain an implicit interest rate, the Company estimates its incremental borrowing rate based on information available at commencement date in determining the present value of future payments. The Company includes options to extend the lease in the lease liability and right-of-use asset when it is reasonably certain that the option will be exercised. Operating lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Finance lease assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or, in the instance where title does not transfer at the end of the lease term, the lease term. The interest component of a finance lease is included in interest expense and recognized using the effective interest method over the lease term. For our short-term leases, we recognize lease payments as an expense on a straight-line basis over the lease term.
Net Loss Per Share	Net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding. Convertible notes, outstanding options to purchase common stock, restricted stock units and common stock warrants have not been included in the calculation of diluted net loss per share because to do so would be anti-dilutive. Accordingly, the numerator and the denominator used in computing both basic and diluted net loss per share for each period are the same.
Fair Value Measurements	The Company establishes the fair value of its assets and liabilities using the price that would be received to sell an asset or paid to transfer a financial liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy is used to measure fair value. The three levels of the fair value hierarchy are as follows: • Level 1 — Quoted prices in active markets for identical assets and liabilities. • Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. • Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The recorded amounts of certain financial instruments, including cash, accounts receivable, prepaid expenses and other, accounts payable and accrued liabilities, approximate fair value due to their relatively short-term maturities. The recorded amount of the Company’s long-term debt can be determined based on the estimated or actual bid prices of the Convertible Senior Notes in an over-the-counter market, which are classified as a Level 2 financial instrument.
Internal Use Software, Policy	The Company capitalizes certain development costs incurred in connection with software development for internal use software platforms. Costs incurred in the preliminary stages of development are expensed as incurred. Once software has reached the development stage, internal and external costs, if direct, are capitalized until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized internal use software development costs are included in property and equipment and are amortized on a straight-line basis over the estimated useful life and are included in depreciation and amortization within operating expenses in our consolidated statements of operations. Capitalized internal use software development costs were $10.2 million and $4.0 million as of September 30, 2022 and December 31, 2021, respectively.Capitalized costs associated with the implementation of hosted third-party cloud computing arrangements are recorded as part of current and long-term other assets. Implementation costs are amortized on a straight-line basis over the term of the related hosting arrangement and included within the consolidated statements of operations based on the functional use of the software. Unamortized capitalized software implementation costs were $2.7 million and $3.2 million as of September 30, 2022 and December 31, 2021, respectively. Maintenance and training costs are expensed as incurred.

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	9 Months Ended
Revenue from Contracts with Customers (Tables)	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table provides information about disaggregated revenue by major product line and primary geographic market (in thousands): Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Americas Europe and Middle East Asia Pacific Total Americas Europe and Middle East Asia Pacific Total Product revenue: Instruments $ 4,835 $ 2,171 $ 1,017 $ 8,023 $ 16,343 $ 6,132 $ 4,189 $ 26,664 Consumables 12,044 3,687 851 16,582 37,017 11,778 3,102 51,897 Total product revenue 16,879 5,858 1,868 24,605 53,360 17,910 7,291 78,561 Service revenue 3,362 1,259 240 4,861 9,589 3,486 669 13,744 Total product and service revenue 20,241 7,117 2,108 29,466 62,949 21,396 7,960 92,305 Collaboration revenue 75 — — 75 535 — — 535 Total revenues $ 20,316 $ 7,117 $ 2,108 $ 29,541 $ 63,484 $ 21,396 $ 7,960 $ 92,840 Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 Americas Europe and Middle East Asia Pacific Total Americas Europe and Middle East Asia Pacific Total Product revenue: Instruments $ 8,514 $ 3,827 $ 2,154 $ 14,495 $ 21,650 $ 10,230 $ 6,176 $ 38,056 Consumables 13,120 3,682 1,226 18,028 36,928 11,538 3,506 51,972 Total product revenue 21,634 7,509 3,380 32,523 58,578 21,768 9,682 90,028 Service revenue 2,957 1,149 295 4,401 8,138 3,010 774 11,922 Total product and service revenue 24,591 8,658 3,675 36,924 66,716 24,778 10,456 101,950 Collaboration revenue 226 — — 226 680 — — 680 Total revenues $ 24,817 $ 8,658 $ 3,675 $ 37,150 $ 67,396 $ 24,778 $ 10,456 $ 102,630

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
Net Loss Per Share (Tables)	Sep. 30, 2022
Earnings Per Share [Abstract]
Summary of Shares Underlying Outstanding Options and Warrants were Excluded from Computation of Basic and Diluted Net Loss Per Share	The following shares were excluded from the computation of basic and diluted net loss per share for the periods presented (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Options to purchase common stock 1,788 2,138 1,866 2,349 Restricted stock units 2,218 1,318 1,777 1,356 Common stock warrants 471 471 471 471

Short-term Investments (Tables)

Short-term Investments (Tables)	9 Months Ended
Short-term Investments (Tables)	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Debt Securities, Available-for-sale	Short-term investments consisted of available-for-sale and equity securities as follows (in thousands): Type of securities as of September 30, 2022 Amortized Gross Gross Fair value Corporate debt securities $ 80,363 $ — $ (841) $ 79,522 Government-related debt securities 31,039 — (423) 30,616 Asset-backed securities 3,283 — (37) 3,246 Total available-for-sale debt securities $ 114,685 $ — $ (1,301) $ 113,384 Type of securities as of December 31, 2021 Amortized Gross Gross Fair value Corporate debt securities $ 177,375 $ 3 $ (195) $ 177,183 Government-related debt securities 33,134 2 (97) 33,039 Asset-backed securities 31,631 — (32) 31,599 Total available-for-sale debt securities $ 242,140 $ 5 $ (324) $ 241,821
Fair Values of Available-for-Sale Securities by Contractual Maturity	The fair values of available-for-sale debt securities by contractual maturity were as follows (in thousands): September 30, 2022 December 31, 2021 Maturing in one year or less $ 110,138 $ 174,534 Maturing in one to three years 3,246 67,287 Total available-for-sale debt securities $ 113,384 $ 241,821
Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value	The following table summarizes investments that have been in a continuous unrealized loss position as of September 30, 2022 (in thousands). Less than 12 months 12 months or greater Total Fair Value Gross unrealized losses Fair Value Gross unrealized losses Fair Value Gross unrealized losses Corporate debt securities $ 44,749 $ (521) $ 14,825 $ (320) $ 59,574 $ (841) Government-related debt securities 22,636 (391) 7,981 (32) 30,617 (423) Asset Backed Securities 3,246 (37) — — 3,246 (37) Total $ 70,631 $ (949) $ 22,806 $ (352) $ 93,437 $ (1,301)

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
Fair Value Measurements (Tables)	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Company's Available-for-Sale Securities by Level within Fair Value Hierarchy	The Company’s investments by level within the fair value hierarchy were as follows (in thousands): Fair value measurement using: Type of securities as of September 30, 2022 Level 1 Level 2 Level 3 Total Cash equivalents: Money market fund $ 109,209 $ — $ — $ 109,209 Short-term investments: Corporate debt securities — 79,522 — 79,522 Government-related debt securities — 30,616 — 30,616 Asset-backed securities — 3,246 — 3,246 Total $ 109,209 $ 113,384 $ — $ 222,593 Fair value measurement using: Type of securities as of December 31, 2021 Level 1 Level 2 Level 3 Total Cash equivalents: Money market fund $ 98,247 $ — $ — $ 98,247 Short-term investments: Corporate debt securities — 177,183 — 177,183 Government-related debt securities — 33,039 — 33,039 Asset-backed securities — 31,599 — 31,599 Total $ 98,247 $ 241,821 $ — $ 340,068

Inventory (Tables)

Inventory (Tables)	9 Months Ended
Inventory (Tables)	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory, net of related allowances, consisted of the following as of the date indicated (in thousands): September 30, 2022 December 31, 2021 Raw materials $ 7,507 $ 5,135 Work in process 15,140 9,916 Finished goods 23,114 16,435 Total inventory, net $ 45,761 $ 31,486

Long-term Debt (Tables)

Long-term Debt (Tables)	9 Months Ended
Long-term Debt (Tables)	Sep. 30, 2022
Debt Disclosure [Abstract]
Components of Borrowings, Including Current Portion	The outstanding balances of the Company’s Convertible Notes and previously outstanding term loan consisted of the following (in thousands): September 30, 2022 December 31, 2021 Outstanding principal of Convertible Note $ 230,000 $ 230,000 Less: unamortized issuance costs (3,750) (4,856) Long-term debt, net $ 226,250 $ 225,144
Schedule of Interest Expense	The following table sets forth total interest expense recognized related to the Convertible Notes (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Contractual interest expense $ 1,509 $ 1,509 $ 4,528 $ 4,528 Amortization of issuance costs 373 361 1,105 1,069 Total interest expense $ 1,882 $ 1,870 $ 5,633 $ 5,597

Description of Business - Addit

Description of Business - Additional Information (Details)	9 Months Ended
Description of Business - Additional Information (Details)	Sep. 30, 2022 platform
Equity [Abstract]
Number of platforms	2

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Significant Accounting Policies [Line Items]
Capitalized Computer Software, Net	$ 2,700,000	$ 3,200,000
Software Development
Significant Accounting Policies [Line Items]
Capitalized Computer Software, Gross	$ 10,200,000	$ 4,000,000

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Narrative (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) sales_force	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Disaggregation of Revenue [Line Items]
Number Of Sales Forces \| sales_force			1
Contract liabilities	$ (11,400)		$ (11,400)		$ (10,300)
Customer deposits	1,071		1,071		1,278
Increase in contract with customer liability			800
Cash payments received form customers			9,600
Performance obligation satisfied in previous period			8,800
Contract assets	1,000		$ 1,000		$ 700
Revenue, Performance Obligation, Description of Payment Terms			45 days
UNITED STATES
Disaggregation of Revenue [Line Items]
Revenues	19,000	$ 60,900	$ 23,900	$ 65,000
Total Products And Services
Disaggregation of Revenue [Line Items]
Remaining performance obligation	$ 12,500		$ 12,500

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Schedule of Disaggregated Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 29,541	$ 37,150	$ 92,840	$ 102,630
Total product and service revenue
Disaggregation of Revenue [Line Items]
Revenue	29,466	36,924	92,305	101,950
Total product revenue
Disaggregation of Revenue [Line Items]
Revenue	24,605	32,523	78,561	90,028
Instruments
Disaggregation of Revenue [Line Items]
Revenue	8,023	14,495	26,664	38,056
Consumables
Disaggregation of Revenue [Line Items]
Revenue	16,582	18,028	51,897	51,972
Service revenue
Disaggregation of Revenue [Line Items]
Revenue	4,861	4,401	13,744	11,922
Collaboration revenue
Disaggregation of Revenue [Line Items]
Revenue	75	226	535	680
Americas
Disaggregation of Revenue [Line Items]
Revenue	20,316	24,817	63,484	67,396
Americas \| Total product and service revenue
Disaggregation of Revenue [Line Items]
Revenue	20,241	24,591	62,949	66,716
Americas \| Total product revenue
Disaggregation of Revenue [Line Items]
Revenue	16,879	21,634	53,360	58,578
Americas \| Instruments
Disaggregation of Revenue [Line Items]
Revenue	4,835	8,514	16,343	21,650
Americas \| Consumables
Disaggregation of Revenue [Line Items]
Revenue	12,044	13,120	37,017	36,928
Americas \| Service revenue
Disaggregation of Revenue [Line Items]
Revenue	3,362	2,957	9,589	8,138
Americas \| Collaboration revenue
Disaggregation of Revenue [Line Items]
Revenue	75	226	535	680
Europe and Middle East
Disaggregation of Revenue [Line Items]
Revenue	7,117	8,658	21,396	24,778
Europe and Middle East \| Total product and service revenue
Disaggregation of Revenue [Line Items]
Revenue	7,117	8,658	21,396	24,778
Europe and Middle East \| Total product revenue
Disaggregation of Revenue [Line Items]
Revenue	5,858	7,509	17,910	21,768
Europe and Middle East \| Instruments
Disaggregation of Revenue [Line Items]
Revenue	2,171	3,827	6,132	10,230
Europe and Middle East \| Consumables
Disaggregation of Revenue [Line Items]
Revenue	3,687	3,682	11,778	11,538
Europe and Middle East \| Service revenue
Disaggregation of Revenue [Line Items]
Revenue	1,259	1,149	3,486	3,010
Europe and Middle East \| Collaboration revenue
Disaggregation of Revenue [Line Items]
Revenue	0	0	0	0
Asia Pacific
Disaggregation of Revenue [Line Items]
Revenue	2,108	3,675	7,960	10,456
Asia Pacific \| Total product and service revenue
Disaggregation of Revenue [Line Items]
Revenue	2,108	3,675	7,960	10,456
Asia Pacific \| Total product revenue
Disaggregation of Revenue [Line Items]
Revenue	1,868	3,380	7,291	9,682
Asia Pacific \| Instruments
Disaggregation of Revenue [Line Items]
Revenue	1,017	2,154	4,189	6,176
Asia Pacific \| Consumables
Disaggregation of Revenue [Line Items]
Revenue	851	1,226	3,102	3,506
Asia Pacific \| Service revenue
Disaggregation of Revenue [Line Items]
Revenue	240	295	669	774
Asia Pacific \| Collaboration revenue
Disaggregation of Revenue [Line Items]
Revenue	$ 0	$ 0	$ 0	$ 0

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Shares Underlying Outstanding Options and Warrants were Excluded from Computation of Basic and Diluted Net Loss Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share (in shares)	1,788	2,138	1,866	2,349
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share (in shares)	2,218	1,318	1,777	1,356
Common stock warrants \| Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share (in shares)	471	471	471	471

Short-term Investments - Availa

Short-term Investments - Available-for-Sale Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Amortized cost	$ 114,685	$ 242,140
Gross unrealized gains	0	5
Gross unrealized losses	(1,301)	(324)
Fair value	113,384	241,821
Corporate debt securities
Debt Securities, Available-for-sale [Line Items]
Amortized cost	80,363	177,375
Gross unrealized gains	0	3
Gross unrealized losses	(841)	(195)
Fair value	79,522	177,183
Government-related debt securities
Debt Securities, Available-for-sale [Line Items]
Amortized cost	31,039	33,134
Gross unrealized gains	0	2
Gross unrealized losses	(423)	(97)
Fair value	30,616	33,039
Asset-backed Securities
Debt Securities, Available-for-sale [Line Items]
Amortized cost	3,283	31,631
Gross unrealized gains	0	0
Gross unrealized losses	(37)	(32)
Fair value	$ 3,246	$ 31,599

Short-term Investments - Fair V

Short-term Investments - Fair Values of Available-for-Sale Securities by Contractual Maturity (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Maturing in one year or less	$ 110,138	$ 174,534
Maturing in one to three years	3,246	67,287
Total available-for-sale debt securities	$ 113,384	$ 241,821

Short-term Investments - Summar

Short-term Investments - Summary of Investments in a Continuous Loss Position (Details)	Sep. 30, 2022 USD ($)
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	$ 70,631,000
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	(949,000)
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value	22,806,000
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	(352,000)
Total, Fair value	93,437,000
Total, Gross unrealized losses	(1,301,000)
Corporate debt securities
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	44,749,000
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	(521,000)
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value	14,825,000
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	(320,000)
Total, Fair value	59,574,000
Total, Gross unrealized losses	(841,000)
US Government Debt Securities
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	22,636,000
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	(391,000)
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value	7,981,000
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	(32,000)
Total, Fair value	30,617,000
Total, Gross unrealized losses	(423,000)
Asset-backed Securities
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	3,246,000
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	(37,000)
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value	0
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	0
Total, Fair value	3,246,000
Total, Gross unrealized losses	$ (37,000)

Fair Value Measurements - Compa

Fair Value Measurements - Company's Available-for-Sale Securities by Level within Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Mar. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	$ 113,384	$ 241,821
Total	222,593	340,068
Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	79,522	177,183
US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	30,616	33,039
Asset-backed Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	3,246	31,599
Financial Instruments, Owned, Mortgages, Mortgage-backed and Asset-backed Securities, at Fair Value	3,246	31,599
Money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	109,209	98,247
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	109,209	98,247
Level 1 \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	0	0
Level 1 \| US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	0	0
Level 1 \| Asset-backed Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Instruments, Owned, Mortgages, Mortgage-backed and Asset-backed Securities, at Fair Value	0	0
Level 1 \| Money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	109,209	98,247
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	113,384	241,821
Level 2 \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	79,522	177,183
Level 2 \| US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	30,616	33,039
Level 2 \| Asset-backed Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Instruments, Owned, Mortgages, Mortgage-backed and Asset-backed Securities, at Fair Value	3,246	31,599
Level 2 \| Money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	0	0
Level 3 \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	0	0
Level 3 \| US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	0	0
Level 3 \| Asset-backed Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Instruments, Owned, Mortgages, Mortgage-backed and Asset-backed Securities, at Fair Value	0	0
Level 3 \| Money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	$ 0
Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt fair value	$ 194,900
Senior Notes \| Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument face amount			$ 230,000

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 7,507	$ 5,135
Work in process	15,140	9,916
Finished goods	23,114	16,435
Inventory, net	$ 45,761	$ 31,486

Long-term Debt - Additional Inf

Long-term Debt - Additional Information (Details) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 31, 2020 USD ($) $ / shares	Sep. 30, 2022 USD ($) $ / shares	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) $ / shares	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Dec. 31, 2021 $ / shares
Line of Credit Facility [Line Items]
Common stock, par value (in dollars per share) \| $ / shares		$ 0.0001		$ 0.0001			$ 0.0001
Share price (in usd per share) \| $ / shares		$ 12.77		$ 12.77
Convertible Notes
Line of Credit Facility [Line Items]
Debt issuance costs			$ 7,400		$ 7,400
Debt term				5 years
Effective interest rate				3.30%
Interest Expense, Debt		$ 1,882	1,870	$ 5,633		$ 5,597
Contractual interest expense		1,509	1,509	4,528	4,528
Amortization of issuance costs		$ 373	$ 361	$ 1,105	$ 1,069
Senior Notes \| Convertible Notes
Line of Credit Facility [Line Items]
Debt instrument face amount	$ 230,000
Proceeds from issuance of debt	$ 222,600
Debt instrument stated rate							2.625%
Conversion ratio	20.9161
Common stock, par value (in dollars per share) \| $ / shares	$ 0.0001
Conversion price \| $ / shares	$ 47.81

Long-term Debt - Components of

Long-term Debt - Components of Borrowings, Including Current Portion (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Long-term debt, net of discounts	$ 226,250	$ 225,144
Convertible Notes
Debt Instrument [Line Items]
Unamortized debt discounts	(3,750)	(4,856)
Long-term debt, net of discounts	226,250	225,144
Convertible Notes
Debt Instrument [Line Items]
Outstanding Principal Of Convertible Debt	$ 230,000	$ 230,000

Long-term Debt - Schedule of In

Long-term Debt - Schedule of Interest (Details) - Convertible Notes - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Debt Instrument [Line Items]
Contractual interest expense	$ 1,509	$ 1,509	$ 4,528	$ 4,528
Amortization of issuance costs	373	361	1,105	$ 1,069
Total interest expense	$ 1,882	$ 1,870	$ 5,633		$ 5,597

Subsequent Event (Details)

Subsequent Event (Details) - Subsequent Event $ in Millions	Nov. 04, 2022 USD ($)
Subsequent Event [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent	10%
Minimum
Subsequent Event [Line Items]
Restructuring and Related Cost, Expected Cost	$ 3
Maximum
Subsequent Event [Line Items]
Restructuring and Related Cost, Expected Cost	$ 4